Timeline secures funding from L’Oréal and Nestlé in pivotal financing round

Swiss longevity biotech plans to use $66 million funding to build Timeline into a leading longevity consumer health brand.

Timeline, a consumer health biotech company developing innovative solutions for healthy aging and longevity, has today announced that it raised CHF 56m (US$ 66m) in an oversubscribed Series D financing round. A significant milestone for the company, the funding includes strategic investments from two global industry leaders – L’Oréal and Nestlé.

The financing round was led by BOLD (Business Opportunities for L’Oréal Development), L’Oréal Groupe’s strategic innovation venture capital fund.

Longevity.Technology: Mitopure contains a proprietary, highly pure form of one of the most promising longevity molecules in the market – urolithin A. Urolithin A has been shown in clinical studies to improve cellular health and human performance by re-energising cells, and it does this by activating mitophagy and improving mitochondrial function. Optimal mitochondrial function is essential for maintaining cellular energy which supports muscle strength, cognition, immune resilience, skin vitality and other important benefits, offering a comprehensive approach to promoting healthspan.

Timeline, which is built on 15 years of research and holds over 50 patents, plans to use the funding to build Timeline into a leading longevity consumer health brand, and expand the science, product categories, and markets across food, beauty and health sectors.

“This strategic collaboration reflects the breakthrough multidimensional approach that we’ve always believed is necessary to make meaningful advancements for longevity and healthspan,” said Patrick Aebischer, Co-Founder and Chairman of Timeline. “I want to thank L’Oréal, Nestlé and our longstanding investors for their commitment to longevity solutions rooted in the highest level of science.”

“Longevity is about living healthier for longer and L’Oréal has been working for a decade to understand and anticipate what this could mean for beauty,” said Barbara Lavernos, Deputy Chief Executive Officer and in charge of Research, Innovation and Technology, L’Oréal.

“Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analyzing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”

“We have been an investor in Timeline since 2019 and continue to be very impressed with the team and stand behind the exponential potential that the Mitopure technology holds for nutrition to help people age better,” said Anna Mohl, CEO of Nestlé Health Science. “We’re excited to have L’Oréal join as an investor and strategic partner to bring this technology to new heights and extend its applications.”